The in vitro activities of ofloxacin alone and in combination with metronidazole against 177 anaerobic bacteria isolated from intra-abdominal infections, as determined by broth microdilution, showed that some Bacteroidesfragiis strains were susceptible and that most other B. fragiis group species strains were resistant to ofloxacin. Isolates of other anaerobic species and genera, including those causing female genital tract disease, were generally susceptible to ofloxacin. Ofloxacin in combination with metronidazole usually showed an additive or indifferent interaction but no antagonism.
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Ofloxacin is a fluoroquinolone antimicrobial agent with a broad spectrum of activity against gram-positive and gramnegative aerobic bacteria (2, 4, 6, 8) . Its activity against anaerobic bacteria is less well described (2, 4, 6, 8) . Generally, ofloxacin, as well as the other fluoroquinolones such as norfloxacin and ciprofloxacin, is less active against anaerobic bacteria than against aerobes (4, 6) . Ofloxacin is likely to be used for selective decontamination of the bowel in neutropenic patients (7, 11, 13) and in combination with other agents, especially metronidazole, in clinical settings involving mixed aerobic-anaerobic bacteria. It is therefore important to ascertain the in vitro activities of ofloxacin against a wide variety of common clinical anaerobic isolates, as well as the effect of its combination with metronidazole. We therefore explored its activity, using a broth microdilution and checkerboard assay.
A total of 177 anaerobic bacteria, all recently isolated from intra-abdominal infections of patients hospitalized at Santa Monica Hospital Medical Center and St. John's Hospital & Health Center of Santa Monica, were studied (see Table 1 ). All isolates were identified by standard criteria (5, 10 (12) found with ciprofloxacin and metronidazole. This lack of synergy may be related to the excellent activity of metronidazole against almost all anaerobic bacteria.
Some studies have suggested that ofloxacin be used for selective decontamination of the gastrointestinal tract in neutropenic patients (1, 2, 7, 13) . Even though ofloxacin exhibited moderate activity against many fecal anaerobic bacteria, several studies have noted that ofloxacin did not alter the anaerobic fecal flora in healthy volunteers (7, 11) . This is consistent with our prior findings (3) for another fluoroquinolone (norfloxacin) with a marked inoculum effect against fecal anaerobic bacteria, causing the MIC to be even greater than the level attained in the feces. Edlund et al. (1) suggested an alternate mechanism due to binding of the quinolones to the feces, thereby decreasing the quinolones' effective local activity. van Saene et al. (11) found ofloxacin to cause less disturbance to the normal anaerobic bowel flora (possibly because of the relatively greater activity of ciprofloxacin than of ofloxacin against anaerobes, as well as the lower absorption rate of ciprofloxacin than of ofloxacin), leading to higher fecal antibiotic levels.
While the isolates studied were from intra-abdominal sources, some of these anaerobic species, including Prevotella intermedia, Prevotella melaninogenicus, Prevotella bivius, Porphyromonas asaccharolytica, and Peptostreptococcus species, are also causes of female genital tract infection. These isolates were generally susceptible to ofloxacin. This activity against anaerobic bacteria, coupled with the activity against aerobic bacteria, gonococci, and chlamydia, suggests that ofloxacin may be effective in treatment of female genital tract infections.
